Moderna's Hantavirus Vaccine Research Sparks Investor Optimism
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy MRNA?
Source: stocktwits
Moderna Inc. shares surged 9.13% in pre-market trading, reaching a 20-day high, following the announcement of its hantavirus vaccine research in collaboration with the U.S. Army Medical Research Institute. This development has generated significant investor interest, reflecting optimism about the company's future in the vaccine market. Despite the ongoing challenges with declining sales from its COVID-19 vaccines, which dropped from $19.26 billion in 2022 to an expected $3.24 billion in 2024, the renewed focus on innovative vaccine solutions amid a hantavirus outbreak has positioned Moderna favorably in the eyes of investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRNA
Wall Street analysts forecast MRNA stock price to fall
20 Analyst Rating
1 Buy
16 Hold
3 Sell
Hold
Current: 54.350
Low
17.00
Averages
32.47
High
63.00
Current: 54.350
Low
17.00
Averages
32.47
High
63.00
About MRNA
Moderna, Inc. is a biotechnology company advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). It also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. It has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
US Stocks Edge Up as Chipmakers Lead Market Rally
- Chip Stocks Rally: Chip leaders like Nvidia and Intel continue their upward momentum in an AI-driven market, supporting gains for the S&P 500 and Nasdaq despite ongoing concerns about global oil supply disruptions.
- Analyst Upgrades Boost Qualcomm: Qualcomm surged following an analyst upgrade, reflecting strong market expectations for AI memory demand, with analysts discussing a potential supercycle in the sector that enhances investor confidence.
- Biotech Stocks Surge: Moderna jumped in early trading as investors express optimism about its early hantavirus research, with the stock gaining over 15% in the past five days, highlighting market interest in biotech innovation.
- Oil Price Surge Affects Markets: Oil prices rose nearly 3% by midday, with WTI crude trading at $98 a barrel, amid heightened concerns over stalled U.S.-Iran negotiations, as analysts stress the importance of reopening the Strait of Hormuz.
See More
US Stocks Rise Slightly, Nasdaq Hits All-Time High
- Market Performance: The S&P 500 Index rose by 0.25% and the Nasdaq 100 Index increased by 0.17%, reaching all-time highs, reflecting strong corporate earnings and optimism around artificial intelligence, although rising oil prices and bond yields limited gains.
- Middle East Impact: The failure of the US and Iran to reach a peace agreement has led to rising global bond yields, with the 10-year T-note yield increasing by 3 basis points to 4.39%, raising concerns that elevated energy prices could force central banks to tighten monetary policy.
- Chinese Trade Data: China's April exports rose by 14.1% year-on-year and imports increased by 25.3%, both exceeding market expectations, indicating positive signals for global economic recovery that could benefit global markets.
- Earnings Reports: So far, 83% of the 446 S&P 500 companies that reported earnings have beaten estimates, with Q1 earnings projected to climb by 12% year-on-year, although excluding the technology sector, the growth is only 3%, marking the weakest performance in two years.
See More
Trade Desk Downgrade Leads to Stock Plunge
- Trade Desk Downgrade: The stock of Trade Desk fell nearly 7% after HSBC downgraded its rating from hold to reduce and slashed the price target from $31 to $20, indicating about a 13% downside, marking the company's fourth consecutive negative trading day.
- Corning Stock Surge: Corning's shares jumped 10% after Nvidia announced a $3.2 billion investment and a partnership to open three new manufacturing plants, leading to its inclusion in Bank of America's U.S. 1 List, reflecting strong market confidence in its growth prospects.
- Wendy's Rating Cut: JPMorgan downgraded Wendy's from neutral to underweight with a new price target of $6, implying an 18% downside, primarily due to a continued decline in U.S. same-store sales trends and uncertainty about the company's future, resulting in a 6% drop in stock price.
- Circle Internet Group Mixed Results: Circle's stock rose 15% after reporting earnings per share of 21 cents, beating expectations, although its revenue of $694 million fell short of the $722 million forecast, while successfully raising $222 million from various institutions, indicating market confidence in its stablecoin.
See More
Hantavirus Outbreak Sparks Volatility in Biotech Stocks
- Market Reaction: The hantavirus outbreak has triggered investor interest, leading biotech stocks like Moderna, Novavax, and Inovio to rise significantly over the past week, reflecting market sensitivity to vaccine development and speculative sentiment.
- CDC Risk Assessment: The Centers for Disease Control and Prevention (CDC) has stated that the risk of hantavirus transmission is extremely low, emphasizing that infection requires close contact with an infected person, which alleviates some market fears and reduces panic.
- Moderna's Development Update: Moderna announced it is working on a hantavirus treatment, currently in early stages, but its stock surged due to market confidence in its mRNA platform, demonstrating ongoing investor interest in vaccine development.
- Cautious Investor Sentiment: Despite the short-term rise in biotech stocks driven by the outbreak, analysts note that these market fluctuations are sentiment-driven and do not reflect fundamentals, urging investors to be cautious and avoid following the hype blindly.
See More
U.S. Stocks Rise Slightly Amid Strong Corporate Earnings
- Market Performance: The S&P 500 rose by 0.17% and the Nasdaq 100 reached an all-time high, reflecting strong corporate earnings and optimism around AI, although rising oil prices and bond yields limited gains.
- Middle East Impact: The failure of the U.S. and Iran to reach a peace agreement has led to rising global bond yields, with the 10-year Treasury yield increasing to 4.39%, potentially forcing central banks to tighten monetary policy, which could affect market liquidity.
- Chinese Trade Data: China's April exports rose 14.1% year-on-year and imports increased by 25.3%, both exceeding market expectations, providing a positive signal for global economic growth and potentially boosting international investment sentiment.
- Corporate Earnings Situation: So far, 83% of the 446 S&P 500 companies have exceeded earnings expectations, with Q1 earnings projected to grow by 12% year-on-year, demonstrating corporate resilience in the economic recovery, although growth in the tech sector has slowed to 3%.
See More
MNDY Surges on AI-Driven Efficiency Gain
- Earnings Beat: monday.com (MNDY) reported Q1 revenue of $351.3 million, a 24% year-over-year increase that exceeded analyst expectations, showcasing the company's strong performance and growth potential in the market.
- Strategic Shift: Leadership highlighted the transition to consumption-based pricing and the successful rollout of its AI Work Platform as key drivers, which not only enhanced customer satisfaction but also strengthened competitive positioning in the market.
- Operational Leverage: CFO Eliran Glazer noted that internal AI productivity gains allow the company to scale revenue without increasing headcount, indicating a higher operational efficiency achieved in a complex environment.
- Strong Cash Flow: The firm generated over $102 million in adjusted free cash flow, providing substantial capital to further invest in autonomous AI agents, thereby enhancing the sustainability of future growth.
See More
US Stocks Edge Up as Chipmakers Lead Market Rally
- Chip Stocks Rally: Chip leaders like Nvidia and Intel continue their upward momentum in an AI-driven market, supporting gains for the S&P 500 and Nasdaq despite ongoing concerns about global oil supply disruptions.
- Analyst Upgrades Boost Qualcomm: Qualcomm surged following an analyst upgrade, reflecting strong market expectations for AI memory demand, with analysts discussing a potential supercycle in the sector that enhances investor confidence.
- Biotech Stocks Surge: Moderna jumped in early trading as investors express optimism about its early hantavirus research, with the stock gaining over 15% in the past five days, highlighting market interest in biotech innovation.
- Oil Price Surge Affects Markets: Oil prices rose nearly 3% by midday, with WTI crude trading at $98 a barrel, amid heightened concerns over stalled U.S.-Iran negotiations, as analysts stress the importance of reopening the Strait of Hormuz.
See More
US Stocks Rise Slightly, Nasdaq Hits All-Time High
- Market Performance: The S&P 500 Index rose by 0.25% and the Nasdaq 100 Index increased by 0.17%, reaching all-time highs, reflecting strong corporate earnings and optimism around artificial intelligence, although rising oil prices and bond yields limited gains.
- Middle East Impact: The failure of the US and Iran to reach a peace agreement has led to rising global bond yields, with the 10-year T-note yield increasing by 3 basis points to 4.39%, raising concerns that elevated energy prices could force central banks to tighten monetary policy.
- Chinese Trade Data: China's April exports rose by 14.1% year-on-year and imports increased by 25.3%, both exceeding market expectations, indicating positive signals for global economic recovery that could benefit global markets.
- Earnings Reports: So far, 83% of the 446 S&P 500 companies that reported earnings have beaten estimates, with Q1 earnings projected to climb by 12% year-on-year, although excluding the technology sector, the growth is only 3%, marking the weakest performance in two years.
See More
Trade Desk Downgrade Leads to Stock Plunge
- Trade Desk Downgrade: The stock of Trade Desk fell nearly 7% after HSBC downgraded its rating from hold to reduce and slashed the price target from $31 to $20, indicating about a 13% downside, marking the company's fourth consecutive negative trading day.
- Corning Stock Surge: Corning's shares jumped 10% after Nvidia announced a $3.2 billion investment and a partnership to open three new manufacturing plants, leading to its inclusion in Bank of America's U.S. 1 List, reflecting strong market confidence in its growth prospects.
- Wendy's Rating Cut: JPMorgan downgraded Wendy's from neutral to underweight with a new price target of $6, implying an 18% downside, primarily due to a continued decline in U.S. same-store sales trends and uncertainty about the company's future, resulting in a 6% drop in stock price.
- Circle Internet Group Mixed Results: Circle's stock rose 15% after reporting earnings per share of 21 cents, beating expectations, although its revenue of $694 million fell short of the $722 million forecast, while successfully raising $222 million from various institutions, indicating market confidence in its stablecoin.
See More
Hantavirus Outbreak Sparks Volatility in Biotech Stocks
- Market Reaction: The hantavirus outbreak has triggered investor interest, leading biotech stocks like Moderna, Novavax, and Inovio to rise significantly over the past week, reflecting market sensitivity to vaccine development and speculative sentiment.
- CDC Risk Assessment: The Centers for Disease Control and Prevention (CDC) has stated that the risk of hantavirus transmission is extremely low, emphasizing that infection requires close contact with an infected person, which alleviates some market fears and reduces panic.
- Moderna's Development Update: Moderna announced it is working on a hantavirus treatment, currently in early stages, but its stock surged due to market confidence in its mRNA platform, demonstrating ongoing investor interest in vaccine development.
- Cautious Investor Sentiment: Despite the short-term rise in biotech stocks driven by the outbreak, analysts note that these market fluctuations are sentiment-driven and do not reflect fundamentals, urging investors to be cautious and avoid following the hype blindly.
See More
U.S. Stocks Rise Slightly Amid Strong Corporate Earnings
- Market Performance: The S&P 500 rose by 0.17% and the Nasdaq 100 reached an all-time high, reflecting strong corporate earnings and optimism around AI, although rising oil prices and bond yields limited gains.
- Middle East Impact: The failure of the U.S. and Iran to reach a peace agreement has led to rising global bond yields, with the 10-year Treasury yield increasing to 4.39%, potentially forcing central banks to tighten monetary policy, which could affect market liquidity.
- Chinese Trade Data: China's April exports rose 14.1% year-on-year and imports increased by 25.3%, both exceeding market expectations, providing a positive signal for global economic growth and potentially boosting international investment sentiment.
- Corporate Earnings Situation: So far, 83% of the 446 S&P 500 companies have exceeded earnings expectations, with Q1 earnings projected to grow by 12% year-on-year, demonstrating corporate resilience in the economic recovery, although growth in the tech sector has slowed to 3%.
See More
MNDY Surges on AI-Driven Efficiency Gain
- Earnings Beat: monday.com (MNDY) reported Q1 revenue of $351.3 million, a 24% year-over-year increase that exceeded analyst expectations, showcasing the company's strong performance and growth potential in the market.
- Strategic Shift: Leadership highlighted the transition to consumption-based pricing and the successful rollout of its AI Work Platform as key drivers, which not only enhanced customer satisfaction but also strengthened competitive positioning in the market.
- Operational Leverage: CFO Eliran Glazer noted that internal AI productivity gains allow the company to scale revenue without increasing headcount, indicating a higher operational efficiency achieved in a complex environment.
- Strong Cash Flow: The firm generated over $102 million in adjusted free cash flow, providing substantial capital to further invest in autonomous AI agents, thereby enhancing the sustainability of future growth.
See More
